



Reprinted  
March 1, 2016

---

---

## ENGROSSED HOUSE BILL No. 1272

---

DIGEST OF HB 1272 (Updated February 29, 2016 4:53 pm - DI 104)

**Citations Affected:** IC 25-1; IC 25-22.5; IC 25-27.5; IC 25-35.6; IC 35-31.5; IC 35-48.

**Synopsis:** Professional licensing matters. Requires a practitioner to provide the Indiana professional licensing agency (agency) and the practitioner's specific board with certain information concerning continuing education. (Current law requires a practitioner to provide the information to a specific board.) Allows an individual who holds a professional or occupational license and is called to active duty to  
(Continued next page)

**Effective:** July 1, 2016.

---

---

### Zent, Bauer, Davisson, Bacon

(SENATE SPONSORS — BROWN L, HEAD, RANDOLPH LONNIE M)

---

---

January 11, 2016, read first time and referred to Committee on Public Health.  
January 21, 2016, amended, reported — Do Pass.  
January 25, 2016, read second time, amended, ordered engrossed.  
January 26, 2016, engrossed. Read third time, passed. Yeas 95, nays 0.

#### SENATE ACTION

February 8, 2016, read first time and referred to Committee on Commerce & Technology.  
February 22, 2016, reported favorably — Do Pass.  
February 29, 2016, read second time, amended, ordered engrossed.

---

---

EH 1272—LS 6628/DI 109



## Digest Continued

fulfill all continuing education requirements through distance learning. Allows the practitioner's specific board to conduct random audits of license renewals of practitioners required to take continuing education courses. Removes language that limited notification by a facility concerning mammography results only if the patient required follow up care or testing. Adds certain substances to the definition of "synthetic drugs". Makes the small business member of the jobs creation committee a voting member. Removes the requirement that the physician assistant's supervisory agreement specify each name or drug classification being delegated to the physician assistant. Makes changes to the speech-language pathology and audiology board concerning the date a chairperson is selected. Provides that an employee of the agency must keep information concerning a complaint regarding a regulated occupation confidential unless disclosure is required under law, required for the advancement of an investigation, or made to a law enforcement agency that has jurisdiction or is reasonably believed to have jurisdiction over a person or matter involved in the complaint.

**EH 1272—LS 6628/DI 109**



Reprinted  
March 1, 2016

Second Regular Session of the 119th General Assembly (2016)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2015 Regular Session of the General Assembly.

## ENGROSSED HOUSE BILL No. 1272

---

A BILL FOR AN ACT to amend the Indiana Code concerning professions and occupations.

*Be it enacted by the General Assembly of the State of Indiana:*

1 SECTION 1. IC 25-1-4-3, AS AMENDED BY P.L.157-2006,  
2 SECTION 13, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
3 JULY 1, 2016]: Sec. 3. (a) Notwithstanding any other law, a board that  
4 is specifically authorized or mandated to require continuing education  
5 as a condition to renew a registration, certification, or license must  
6 require a practitioner to comply with the following renewal  
7 requirements:

8 (1) The practitioner shall provide the board with a sworn  
9 statement executed by the practitioner that the practitioner has  
10 fulfilled the continuing education requirements required by the  
11 board, **after which the board will forward the sworn statement**  
12 **to the agency (established by IC 25-1-5-3).**

13 (2) The practitioner shall retain copies of certificates of  
14 completion for continuing education courses for three (3) years  
15 from the end of the licensing period for which the continuing  
16 education applied. The practitioner shall provide the board **or**  
17 **agency (established by IC 25-1-5-3)** with copies of the

**EH 1272—LS 6628/DI 109**



1 certificates of completion upon the board's **or agency's** request  
 2 for a compliance audit.

3 (b) Following every license renewal period, the **agency with**  
 4 **consultation from the board shall may** randomly audit for compliance  
 5 more than one percent (1%) but less than ten percent (10%) of the  
 6 practitioners required to take continuing education courses.

7 SECTION 2. IC 25-1-4-3.2, AS AMENDED BY P.L.2-2008,  
 8 SECTION 55, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 9 JULY 1, 2016]: Sec. 3.2. (a) A board or agency regulating a profession  
 10 or occupation under this title or under IC 16 or IC 22 shall require that  
 11 at least one-half (1/2) of all continuing education requirements must be  
 12 allowed by distance learning methods, except for doctors, nurses,  
 13 chiropractors, optometrists, and dentists.

14 (b) **An individual who is called to active duty (as defined by**  
 15 **IC 25-1-12-2) must be allowed to fulfill all continuing education**  
 16 **requirements for professional or occupational licenses**  
 17 **administered through the Indiana professional licensing agency by**  
 18 **distance learning methods.**

19 SECTION 3. IC 25-1-7-10, AS AMENDED BY P.L.227-2015,  
 20 SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 21 JULY 1, 2016]: Sec. 10. (a) Except as provided in section 3(b) or 3(c)  
 22 of this chapter, all complaints and information pertaining to the  
 23 complaints shall be held in strict confidence until the attorney general  
 24 files notice with the board of the attorney general's intent to prosecute  
 25 the licensee.

26 (b) A person in the employ of the office of attorney general, ~~or any~~  
 27 ~~of the boards,~~ **the Indiana professional licensing agency,** or any  
 28 person not a party to the complaint may not disclose or further a  
 29 disclosure of information concerning the complaint unless the  
 30 disclosure is:

- 31 (1) required under law;  
 32 (2) required for the advancement of an investigation; or  
 33 (3) made to a law enforcement agency that has jurisdiction or is  
 34 reasonably believed to have jurisdiction over a person or matter  
 35 involved in the complaint.

36 SECTION 4. IC 25-1-16-7, AS AMENDED BY P.L.112-2014,  
 37 SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 38 JULY 1, 2016]: Sec. 7. (a) The committee consists of the following  
 39 individuals:

- 40 (1) The executive director of the agency or the executive director's  
 41 designee. The executive director or the executive director's  
 42 designee shall serve as chairperson of the committee.



- 1 (2) The director of the office or the director's designee.  
 2 (3) The attorney general or the attorney general's designee, as a  
 3 nonvoting member.  
 4 (4) An individual appointed by the governor who represents an  
 5 association that has small businesses, small business owners, or  
 6 licensed professionals as a majority of its members. ~~as a~~  
 7 ~~nonvoting member~~. The member serves at the pleasure of the  
 8 governor.  
 9 (5) Two (2) individuals appointed by the governor who are  
 10 licensed in a regulated occupation.  
 11 (6) Two (2) individuals appointed by the governor who are not  
 12 licensed in a regulated occupation.  
 13 (b) The term of a member appointed under subsection (a)(5) or  
 14 (a)(6) is three (3) years.  
 15 (c) The affirmative votes of a majority of the voting members  
 16 appointed to the committee are required for the committee to take  
 17 action on any measure.  
 18 (d) Notwithstanding any other law, the term of a member appointed  
 19 before July 1, 2014, under subsection (a)(5) or (a)(6) expires on July 1,  
 20 2014.  
 21 SECTION 5. IC 25-22.5-13.2-1, AS ADDED BY P.L.126-2013,  
 22 SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 23 JULY 1, 2016]: Sec. 1. A facility that performs a mammography  
 24 examination shall, if the patient is determined by the facility to have an  
 25 amount of breast and connective tissue in comparison to fat in the  
 26 breast, ~~that would require follow up care or testing~~, notify the patient  
 27 of the determination. The notice required under this section must be  
 28 included with a summary of the written mammography report.  
 29 SECTION 6. IC 25-27.5-5-2, AS AMENDED BY P.L.197-2011,  
 30 SECTION 120, IS AMENDED TO READ AS FOLLOWS  
 31 [EFFECTIVE JULY 1, 2016]: Sec. 2. (a) A physician assistant must  
 32 engage in a dependent practice with physician supervision. A physician  
 33 assistant may perform, under the supervision of the supervising  
 34 physician, the duties and responsibilities that are delegated by the  
 35 supervising physician and that are within the supervising physician's  
 36 scope of practice, including prescribing and dispensing drugs and  
 37 medical devices. A patient may elect to be seen, examined, and treated  
 38 by the supervising physician.  
 39 (b) If a physician assistant determines that a patient needs to be  
 40 examined by a physician, the physician assistant shall immediately  
 41 notify the supervising physician or physician designee.  
 42 (c) If a physician assistant notifies the supervising physician that the



1 physician should examine a patient, the supervising physician shall:

2 (1) schedule an examination of the patient in a timely manner  
3 unless the patient declines; or

4 (2) arrange for another physician to examine the patient.

5 (d) If a patient is subsequently examined by the supervising  
6 physician or another physician because of circumstances described in  
7 subsection (b) or (c), the visit must be considered as part of the same  
8 encounter except for in the instance of a medically appropriate referral.

9 (e) A supervising physician or physician assistant who does not  
10 comply with subsections (b) through (d) is subject to discipline under  
11 IC 25-1-9.

12 (f) A physician assistant's supervisory agreement with a supervising  
13 physician must:

14 (1) be in writing;

15 (2) include all the tasks delegated to the physician assistant by the  
16 supervising physician;

17 (3) set forth the supervisory plans for the physician assistant,  
18 including the emergency procedures that the physician assistant  
19 must follow; and

20 (4) specify the name of the drug or drug classification being  
21 delegated to the physician assistant and the protocol the physician  
22 assistant shall follow in prescribing a drug.

23 (g) The physician shall submit the supervisory agreement to the  
24 board. The physician assistant may prescribe a drug under the  
25 supervisory agreement unless the board denies the supervisory  
26 agreement. Any amendment to the supervisory agreement must be  
27 resubmitted to the board, and the physician assistant may operate under  
28 any new prescriptive authority under the amended supervisory  
29 agreement unless the agreement has been denied by the board.

30 (h) A physician or a physician assistant who violates the supervisory  
31 agreement described in this section may be disciplined under  
32 IC 25-1-9.

33 SECTION 7. IC 25-35.6-2-1 IS AMENDED TO READ AS  
34 FOLLOWS [EFFECTIVE JULY 1, 2016]: Sec. 1. (a) There is  
35 established the speech-language pathology and audiology board.

36 (b) The board shall be comprised of six (6) members, who shall be  
37 appointed by the governor. Five (5) board members shall have been  
38 residents of this state for at least one (1) year immediately preceding  
39 their appointment and shall have been engaged in rendering services  
40 to the public, teaching, or research in speech-language pathology or  
41 audiology for at least five (5) years immediately preceding their  
42 appointment. At least two (2) board members shall be speech-language



1 pathologists and at least two (2) shall be audiologists, with the fifth  
 2 member being either a speech-language pathologist or audiologist. At  
 3 least one (1) of these five (5) members must be engaged in an active  
 4 private practice of speech-language pathology or audiology. The sixth  
 5 member of the board, to represent the general public, shall be a resident  
 6 of this state who has never been associated with speech-language  
 7 pathology or audiology in any way other than as a consumer. Except for  
 8 the member representing the general public, all board members shall  
 9 at all times be holders of active and valid licenses for the practice of  
 10 speech-language pathology or audiology in this state.

11 (c) The governor shall also appoint one (1) nonvoting advisor, who  
 12 must be a licensed physician and board certified in otolaryngology, to  
 13 serve a four (4) year term of office on the board.

14 (d) Appointments shall be for three (3) year terms, with no person  
 15 being eligible to serve more than two (2) full consecutive terms. Terms  
 16 shall begin on the first day of the calendar year and end on the last day  
 17 of the calendar year, except for the first appointed members, who shall  
 18 serve through the last calendar day of the year in which they are  
 19 appointed before commencing the terms prescribed by this subsection.  
 20 Any member of the board may serve until the member's successor is  
 21 appointed and qualified under this chapter.

22 (e) The governor may consider, but shall not be bound to accept,  
 23 recommendations for board membership made by a statewide  
 24 association for speech-language and hearing. A statewide association  
 25 for speech-language and hearing may submit to the governor its  
 26 recommendations for board membership not less than sixty (60) days  
 27 before the end of each calendar year. In the event of a mid-term  
 28 vacancy, such association may make recommendations for filling such  
 29 vacancy.

30 (f) ~~The board shall meet during the first month of each calendar year~~  
 31 ~~to select a chairman and for other appropriate purposes. At least one (1)~~  
 32 ~~additional meeting shall be held before the end of each calendar year.~~  
 33 **At the first meeting of the board each year, members shall elect a**  
 34 **chairperson for the subsequent twelve (12) month period.** Further  
 35 meetings may be convened at the call of the ~~chairman~~ **chairperson** or  
 36 the written request of any two (2) board members. All meetings of the  
 37 board shall be open to the public, except that the board may hold closed  
 38 sessions to prepare, approve, grade, or administer examinations or,  
 39 upon request of an applicant who fails an examination, to prepare a  
 40 response indicating any reason for ~~his~~ **the applicant's** failure. All  
 41 meetings of the board must be held in Indiana.

42 (g) Four (4) members of the board constitute a quorum. A majority



- 1 of the quorum may transact business.  
 2 SECTION 8. IC 35-31.5-2-321, AS AMENDED BY P.L.196-2013,  
 3 SECTION 16, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 4 JULY 1, 2016]: Sec. 321. "Synthetic drug" means:  
 5 (1) a substance containing one (1) or more of the following  
 6 chemical compounds, including an analog of the compound:  
 7 (A) JWH-015 ((2-Methyl-1-propyl-1H-  
 8 indol-3-yl)-1-naphthalenylmethanone).  
 9 (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).  
 10 (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).  
 11 (D) JWH-073  
 12 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).  
 13 (E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol-  
 14 3-yl)methanone).  
 15 (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).  
 16 (G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)-  
 17 naphthalen-1-yl-methanone).  
 18 (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).  
 19 (I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).  
 20 (J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).  
 21 (K) HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl-  
 22 3-(2-methyloctan-2-yl)-  
 23 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).  
 24 (L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl-  
 25 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo  
 26 [c]chromen-1-ol).  
 27 (M) HU-308 ([ (1R,2R,5R)-2-[2,6-dimethoxy-4-  
 28 (2-methyloctan- 2-yl)phenyl]-  
 29 7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).  
 30 (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6-  
 31 (1-methylethenyl)-2-cyclohexen-1-yl]-5  
 32 -pentyl-2,5-cyclohexadiene-1,4-dione).  
 33 (O) CP 55,940  
 34 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-  
 35 5-(2-methyloctan-2-yl)phenol).  
 36 (P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5-  
 37 (2-methyloctan-2-yl)phenol) and its homologues, or  
 38 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)  
 39 phenol, where side chain n=5, and homologues where side  
 40 chain n=4, 6, or 7.  
 41 (Q) WIN 55212-2  
 42 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)





- 1 pyrrolo [1,2,3-de)- 1,4- benzoxazin-  
 2 6-yl]-1-naphthalenylmethanone).  
 3 (R) RCS-4 ((4-methoxyphenyl)  
 4 (1-pentyl-1H-indol-3-yl)methanone).  
 5 (S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H-  
 6 indol-3-yl)-2-(2-methoxyphenyl)ethanone).  
 7 (T) 4-Methylmethcathinone. Other name: mephedrone.  
 8 (U) 3,4-Methylenedioxy-methcathinone. Other name:  
 9 methylone.  
 10 (V) Fluoromethcathinone.  
 11 (W) 4-Methoxymethcathinone. Other name: methedrone.  
 12 (X) 4-Ethylmethcathinone (4-EMC).  
 13 (Y) Methylenedioxy-pyrovalerone. Other name: MDPV.  
 14 (Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.  
 15 (AA) JWH-098, or  
 16 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.  
 17 (BB) JWH-164, or  
 18 1-pentyl-3-(7-methoxy-1-naphthoyl)indole.  
 19 (CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.  
 20 (DD) JWH-201, or  
 21 1-pentyl-3-(4-methoxyphenylacetyl)indole.  
 22 (EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.  
 23 (FF) AM-694, or  
 24 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.  
 25 (GG) CP 50,556-1, or  
 26 [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylp  
 27 ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1  
 28 -yl] acetate.  
 29 (HH) Dimethylheptylpyran, or DMHP.  
 30 (II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.  
 31 (JJ) 6-APB [6-(2-aminopropyl)benzofuran].  
 32 (LL) 7-hydroxymitragynine.  
 33 (MM)  $\alpha$ -PPP [ $\alpha$ -pyrrolidinopropiophenone].  
 34 (NN)  $\alpha$ -PVP (desmethylpyrovalerone).  
 35 (OO) AM-251.  
 36 (PP) AM-1241.  
 37 (QQ) AM-2201.  
 38 (RR) AM-2233.  
 39 (SS) Buphedrone.  
 40 (TT) Butylone.  
 41 (UU) CP-47,497-C7.  
 42 (VV) CP-47,497-C8.



1	(WW) Desoxyipradol.
2	(XX) Ethylone.
3	(YY) Eutylone.
4	(ZZ) Flephedrone.
5	(AAA) JWH-011.
6	(BBB) JWH-020.
7	(CCC) JWH-022.
8	(DDD) JWH-030.
9	(EEE) JWH-182.
10	(FFF) JWH-302.
11	(GGG) MDAI [5,6-methylenedioxy-2-aminoindane].
12	(HHH) Mitragynine.
13	(III) Naphyrone.
14	(JJJ) Pentedrone.
15	(LLL) Pentylone.
16	(MMM) Methoxetamine
17	[2-(3-methoxyphenyl)-2-(ethylamino)- cyclohexanone].
18	(NNN) A796,260 [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-
19	(2,2,3,3-tetramethylcyclopropyl)methanone].
20	(OOO) AB-001[(1s,3s)-adamantan-1-yl]
21	(1-pentyl-1H-indol-3-yl)methanone] or [1-Pentyl-3-
22	(1-adamantoyl)indole].
23	(PPP) AM-356 [Methanandamide].
24	(QQQ) AM 1248 [1-[(1-methyl-2- piperidinyl) methyl]-
25	1H-indol-3-yl] tricyclo[3.3.1.1 <sup>3,7</sup> ] dec-1-yl-methanone]or
26	[(1-[(N-methylpiperindin-2-yl)
27	Methyl]-3-(Adamant-1-oyl)indole]].
28	(RRR) AM 2233 Azepane isomer [(2-iodophenyl)
29	(1-(1-methylazepan-3-yl)- 1H-indol-3-yl)methanone].
30	(SSS) CB-13 [1-Naphthalenyl
31	[4-(pentyoxy)- 1-naphthalenyl]methanone].
32	(TTT) UR-144 [(1-pentyl-1H-indol-3-yl)
33	(2,2,3,3-tetramethylcyclopropyl)-methanone].
34	(UUU) URB 597 [(3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
35	cyclohexylcarbamate].
36	(VVV) URB602 [[1,1'-biphenyl]- 3-yl-carbamic acid,
37	cyclohexyl ester].
38	(WWW) URB 754 [6-methyl-2-[(4-methylphenyl)
39	amino]-1-benzoxazin-4-one].
40	(XXX) XLR-11 or 5-fluoro UR-144
41	(1-(5-fluoropentyl)-1H-indol-3-yl)
42	(2,2,3,3-tetramethylcyclopropyl)methanone].



1 (YYY) AKB48 (Other names include:  
 2 N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide;  
 3 1-pentyl-N-tricyclo[3.3.1.1<sup>3</sup>.7]dec-1-yl-1H-indazole-3-  
 4 carboxamide).  
 5 (ZZZ) 25I-NBOMe (Other names include:  
 6 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-  
 7 benzeneethanamine);  
 8 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)  
 9 methyl]ethanamine).  
 10 (AAAA) 2C-C-NBOMe (Other names include: 25C-NBOMe;  
 11 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)  
 12 methyl]ethanamine;  
 13 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)  
 14 phenethylamine).  
 15 (BBBB) 2NE-1 (Other names include: 1-Pentyl-3-  
 16 (1-adamantylamido)indole).  
 17 (CCCC) STS-135 (Other names include:  
 18 N-Adamantyl-1-fluoropentylindole-3- carboxamide  
 19 (1-5-fluoropentyl)-N-tricyclo[3.3.1.1<sup>3</sup>.7]dec-1-yl-1H-  
 20 indole-3-carboxamide).  
 21 **(DDDD) PB-22 (Other names include:**  
 22 **1-Pentyl-8-quinolinyl ester-1H-indole-2-carboxylic acid).**  
 23 **(EEEE) 5-Fluoro-PB-22 (Other names include:**  
 24 **1-(5-Fluoropentyl)-8-quinolinyl ester 1H-indole-3-carboxylic**  
 25 **acid).**  
 26 **(FFFF) Benocyclidine (Other names include: BCP, BTCP,**  
 27 **and Benzothiophenylcyclohexylpiperidine).**  
 28 **(GGGG) 25B-NBOMe (Other names include:**  
 29 **2C-B-NBOMe and 4-Bromo-2,**  
 30 **5-dimethoxy-N-[(2-Methoxyphenyl)methyl]**  
 31 **benzeneethanamine).**  
 32 **(HHHH) APB (Other names include; (2-Aminopropyl)**  
 33 **Benzofuran).**  
 34 **(III) AB-PINACA**  
 35 **(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-**  
 36 **indazole-3-carboxamide.**  
 37 **(JJJJ) AB-FUBINACA**  
 38 **(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenz**  
 39 **yl)-1H-indazole-3-carboxamide).**  
 40 **(KKKK) ADB-PINACA**  
 41 **(N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H**  
 42 **-indaole-3-carboxamide).**



- 1 (LLLL) Fluoro ADBICA (N-(1-Amino-3,3-  
2 dimethyl-1-oxobutan-2-yl)-(fluoropentyl)-1H-indole-3-  
3 carboxamide).
- 4 (MMMM) APDB (Other names include: -EMA,  
5 -Desoxy-MDA, and (2-Aminopropyl)-2,3-  
6 dihydrobenzofuran).
- 7 (NNNN) THJ-2201 (Other names include: AM2201  
8 indazole analog, Fluoropentyl-JWH-018 indazole, and  
9 5-Fluoro-THJ-018).
- 10 (OOOO) AM 2201 benzimidazole analog (Other names  
11 include: FUBIMINA, FTHJ, and (1-(5-fluoropentyl)-1H-  
12 benzo[d]imidazol-2-yl)(naphthalene-1-yl)methanone).
- 13 (PPPP) MN-25 (Other names include: 7-methoxy-1-  
14 [2-(4-morpholinyl)ethyl]-N-[1S, 2S, 4R]-1,3,3-  
15 trimethylbicyclo[2.2.1]hept-2-yl]-1H-indole-3-carboxamide  
16 and UR-12).
- 17 (QQQQ) FUB-PB-22 (Other names include:  
18 Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).
- 19 (RRRR) FUD-PB-22 (Other names include:  
20 Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxy-  
21 late).
- 22 (SSSS) 5-Fluoro-AB-PINACA (Other names include:  
23 AB-PINACA 5-fluoro analog and N-(1-amino-3-methyl-  
24 oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carbox-  
25 amide).
- 26 (TTTT) 4-MePPP (Other names include:  
27 4-methyl-alpha-pyrrolidinopropiophenone).
- 28 (UUUU) alpha-PBP (Other names include:  
29 Alpha-pyrrolidinobutiophenone).
- 30 (VVVV) AB-CHMINACA (Other names include:  
31 (N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylme-  
32 thyl)-1H-indazole-3-carboxamide).
- 33 (WWWW) Acetyl fentanyl (Other names include:  
34 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
- 35 (2) Any compound structurally derived from  
36 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by  
37 substitution at the nitrogen atom of the indole ring by alkyl,  
38 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
39 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
40 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
41 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
42 or not further substituted in the indole ring to any extent and



- 1 whether or not substituted in the naphthyl ring to any extent.  
2 (3) Any compound structurally derived from 3-(1-naphthoyl)  
3 pyrrole by substitution at the nitrogen atom of the pyrrole ring by  
4 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,  
5 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,  
6 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,  
7 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
8 group, whether or not further substituted in the pyrrole ring to any  
9 extent and whether or not substituted in the naphthyl ring to any  
10 extent.  
11 (4) Any compound structurally derived from  
12 1-(1-naphthylmethyl)indene by substitution at the 3-position of  
13 the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,  
14 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,  
15 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
16 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
17 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
18 or not further substituted in the indene ring to any extent and  
19 whether or not substituted in the naphthyl ring to any extent.  
20 (5) Any compound structurally derived from 3-phenylacetylindole  
21 by substitution at the nitrogen atom of the indole ring with alkyl,  
22 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
23 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
24 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
25 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
26 or not further substituted in the indole ring to any extent and  
27 whether or not substituted in the phenyl ring to any extent.  
28 (6) Any compound structurally derived from  
29 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position  
30 of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,  
31 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,  
32 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
33 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
34 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
35 or not substituted in the cyclohexyl ring to any extent.  
36 (7) Any compound containing a 3-(benzoyl)indole structure with  
37 substitution at the nitrogen atom of the indole ring by alkyl,  
38 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
39 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or  
40 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
41 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
42 or not further substituted in the indole ring to any extent and



- 1 whether or not substituted in the phenyl ring to any extent.  
2 (8) Any compound, except bupropion or a compound listed under  
3 a different schedule, structurally derived from  
4 2-aminopropan-1-one by substitution at the 1-position with either  
5 phenyl, naphthyl, or thiophene ring systems, whether or not the  
6 compound is further modified:  
7 (A) by substitution in the ring system to any extent with alkyl,  
8 alkylendioxy, alkoxy, haloalkyl, hydroxyl, or halide  
9 substituents, whether or not further substituted in the ring  
10 system by one or more other univalent substituents;  
11 (B) by substitution at the 3-position with an acyclic alkyl  
12 substituent;  
13 (C) by substitution at the 2-amino nitrogen atom with alkyl,  
14 dialkyl, benzyl, or methoxybenzyl groups; or  
15 (D) by inclusion of the 2-amino nitrogen atom in a cyclic  
16 structure.  
17 (9) Any compound structurally derived from 3-tetramethyl  
18 cyclopropanoylindole with substitution at the nitrogen atom of the  
19 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,  
20 cycloalkylmethyl, cycloalkylethyl,  
21 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl) ethyl,  
22 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-  
23 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether  
24 or not further substituted in the indole ring to any extent and  
25 whether or not substituted in the tetramethylcyclopropyl ring to  
26 any extent.  
27 (10) Any compound containing a N-(1-adamantyl)-  
28 1H-indazole-3-carboxamide structure with substitution at the  
29 nitrogen atom of the indazole ring by an alkyl, haloalkyl,  
30 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
31 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,  
32 1-(N-methyl-2-pyrrolidinyl) methyl,  
33 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
34 group, whether or not further substituted at the nitrogen atom of  
35 the carboxamide to any extent, whether or not further substituted  
36 in the indazole ring to any extent, and whether or not further  
37 substituted on the adamantyl ring system to any extent. An  
38 example of this structural class includes AKB48.  
39 (11) Any compound containing a N-(1-adamantyl)-  
40 1H-indole-3-carboxamide structure with substitution at the  
41 nitrogen atom of the indole ring by an alkyl, haloalkyl,  
42 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



- 1 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,  
 2 1 - ( N - m e t h y l - 2 - p y r r o l i d i n y l ) m e t h y l ,  
 3 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
 4 group, whether or not further substituted at the nitrogen atom of  
 5 the carboxamide to any extent, whether or not further substituted  
 6 in the indole ring to any extent, and whether or not further  
 7 substituted on the adamantyl ring system to any extent. An  
 8 example of this structural class includes STS-135.
- 9 (12) Any compound containing a 3-(1-adamantoyl)indole  
 10 structure with substitution at the nitrogen atom of the indole ring  
 11 by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,  
 12 cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or  
 13 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl,  
 14 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl  
 15 group, whether or not further substituted on the adamantyl ring  
 16 system to any extent. An example of this structural class includes  
 17 AM-1248.
- 18 (13) Any compound determined to be a synthetic drug by rule  
 19 adopted under IC 25-26-13-4.1.
- 20 SECTION 9. IC 35-48-2-4, AS AMENDED BY P.L.283-2013,  
 21 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
 22 JULY 1, 2016]: Sec. 4. (a) The controlled substances listed in this  
 23 section are included in schedule I.
- 24 (b) Opiates. Any of the following opiates, including their isomers,  
 25 esters, ethers, salts, and salts of isomers, esters, and ethers, unless  
 26 specifically excepted by rule of the board or unless listed in another  
 27 schedule, whenever the existence of these isomers, esters, ethers, and  
 28 salts is possible within the specific chemical designation:
- 29 Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-  
 30 piperidinyl]-N-phenylacetamide) (9815)  
 31 Acetylmethadol (9601)  
 32 Allylprodine (9602)  
 33 Alpha-methylthiofentanyl (N-[1-methyl-2-(2-  
 34 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) (9832)  
 35 Alphacetylmethadol (9603)  
 36 Alphameprodine (9604)  
 37 Alphamethadol (9605)  
 38 Alphamethylfentanyl (9814)  
 39 Benzethidine (9606)  
 40 Beta-hydroxy-3-methylfentanyl (9831). Other name:  
 41 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl  
 42 ]-N-phenylpropanamide



1	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
2	phenethyl)-4-piperidinyl]-N-phenylpropanamide) (9830)
3	Betacetylmethadol (9607)
4	Betameprodine (9608)
5	Betamethadol (9609)
6	Betaprodine (9611)
7	Clonitazene (9612)
8	Dextromoramide (9613)
9	Diampromide (9615)
10	Diethylthiambutene (9616)
11	Difenoxin (9168)
12	Dimenoxadol (9617)
13	Dimepheptanol (9618)
14	Dimethylthiambutene (9619)
15	Dioxaphetyl butyrate (9621)
16	Dipipanone (9622)
17	Ethylmethylthiambutene (9623)
18	Etonitazene (9624)
19	Etoxidine (9625)
20	Furethidine (9626)
21	Hydroxypethidine (9627)
22	Ketobemidone (9628)
23	Levomoramide (9629)
24	Levophenacymorphan (9631)
25	3-Methylfentanyl [N-[3-methyl-1-(2-phenylethyl)-4-
26	piperidyl]-N-phenyl-propanimide](9813)
27	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
28	piperidinyl]-N-phenylpropanamide) (9833)
29	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) (9961)
30	Morpheridine (9632)
31	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl),
32	including any isomers, salts, or salts of isomers (9818)
33	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
34	(thenylfentanyl), including any isomers, salts, or salts of isomers
35	(9834)
36	Noracymethadol (9633)
37	Norlevorphanol (9634)
38	Normethadone (9635)
39	Norpipanone (9636)
40	Para-fluorofentanyl (N-(4-fluorophenyl)-N-
41	[1-(2-phenethyl)-4-piperidinyl] propanamide (9812)
42	Phenadoxone (9637)





- 1 Phenampromide (9638)
- 2 Phenomorphan (9647)
- 3 Phenoperidine (9641)
- 4 PEPAP [1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine] (9663)
- 5 Piritramide (9642)
- 6 Proheptazine (9643)
- 7 Properidine (9644)
- 8 Propiram (9649)
- 9 Racemoramide (9645)
- 10 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
- 11 piperidinyl]-propanamide) (9835)
- 12 Tilidine (9750)
- 13 Trimeperidine (9646)

14 (c) Opium derivatives. Any of the following opium derivatives, their  
 15 salts, isomers, and salts of isomers, unless specifically excepted by rule  
 16 of the board or unless listed in another schedule, whenever the  
 17 existence of these salts, isomers, and salts of isomers is possible within  
 18 the specific chemical designation:

- 19 Acetorphine (9319)
- 20 Acetyldihydrocodeine (9051)
- 21 Benzylmorphine (9052)
- 22 Codeine methylbromide (9070)
- 23 Codeine-N-Oxide (9053)
- 24 Cyprenorphine (9054)
- 25 Desomorphine (9055)
- 26 Dihydromorphine (9145)
- 27 Drotebanol (9335)
- 28 Etorphine (except hydrochloride salt) (9056)
- 29 Heroin (9200)
- 30 Hydromorphanol (9301)
- 31 Methyldesorphine (9302)
- 32 Methyldihydromorphine (9304)
- 33 Morphine methylbromide (9305)
- 34 Morphine methylsulfonate (9306)
- 35 Morphine-N-Oxide (9307)
- 36 Myrophine (9308)
- 37 Nicocodeine (9309)
- 38 Nicomorphine (9312)
- 39 Normorphine (9313)
- 40 Pholcodine (9314)
- 41 Thebacon (9315)

42 (d) Hallucinogenic substances. Unless specifically excepted or



1 unless listed in another schedule, any material, compound, mixture, or  
 2 preparation which contains any quantity of the following  
 3 hallucinogenic, psychedelic, or psychogenic substances, their salts,  
 4 isomers, and salts of isomers whenever the existence of these salts,  
 5 isomers, and salts of isomers is possible within the specific chemical  
 6 designation (for purposes of this subsection only, the term "isomer"  
 7 includes the optical, position, and geometric isomers):

8 (1) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (7473). Other name:  
 9 TCPy.

10 (2) 4-Bromo-2, 5-Dimethoxyamphetamine (7391). Some trade or  
 11 other names: 4-Bromo-2, 5-Dimethoxy-a-methylphenethylamine;  
 12 4-Bromo-2, 5-DMA.

13 (3) 4-Bromo-2, 5-dimethoxyphenethylamine (7392). Some trade  
 14 or other names:

15 2-[4-bromo-2,5-dimethoxyphenyl]-1-aminoethane;  
 16 alpha-desmethyl DOB; 2C-B, Nexus.

17 (4) 2, 5-Dimethoxy-4-ethylamphet-amine (7399). Other name:  
 18 DOET.

19 (5) 2, 5-Dimethoxy-4-(n)-propylthiophenethylamine (7348).  
 20 Other name: 2C-T-7.

21 (6) 2, 5-Dimethoxyamphetamine (7396). Some trade or other  
 22 names: 2, 5-Dimethoxy-a-methylphenethylamine; 2, 5-DMA.

23 (7) 4-Methoxyamphetamine (7411). Some trade or other names:  
 24 4-Methoxy-a-methylphenethylamine; Paramethoxyamphetamine;  
 25 PMA.

26 (8) 5-Methoxy-3, 4-methylenedioxy amphetamine (7401). Other  
 27 Name: MMDA.

28 (9) 5-Methoxy-N, N-diisopropyltryptamine, including any  
 29 isomers, salts, or salts of isomers (7439). Other name:  
 30 5-MeO-DIPT.

31 (10) 4-methyl-2, 5-dimethoxyamphetamine (7395). Some trade  
 32 and other names: 4-methyl-2,

33 5-dimethoxy-a-methylphenethylamine; DOM; and STP.

34 (11) 3, 4-methylenedioxy amphetamine (7400). Other name:  
 35 MDA.

36 (12) 3,4-methylenedioxy-N-ethylamphetamine (7404). Other  
 37 names: N-ethyl-alpha-methyl-3,4(methylenedioxy)  
 38 phenethylamine; N-ethyl MDA; MDE; and MDEA.

39 (13) 3, 4-methylenedioxymethamphetamine (MDMA) (7405).

40 (14) 3, 4, 5-trimethoxy amphetamine (7390). Other name: TMA.

41 (15) Alpha-ethyltryptamine (7249). Some trade and other names:  
 42 Etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine;



- 1 3-(2-aminobutyl) indole; [alpha]-ET; and AET.  
 2 (16) Alpha-methyltryptamine (7432). Other name: AMT.  
 3 (17) Bufotenine (7433). Some trade and other names:  
 4 3-(B-Dimethylaminoethyl)-5-hydroxyindole;  
 5 3-(2-dimethylaminonethyl)-5-indolol; N, N-dimethylserotonin;  
 6 5-hydroxy-N, N-dimethyltryptamine; mappine.  
 7 (18) Diethyltryptamine (7434). Some trade or other names: N,  
 8 N-Diethyltryptamine; DET.  
 9 (19) Dimethyltryptamine (7435). Some trade or other names:  
 10 DMT.  
 11 (20) Ibogaine (7260). Some trade and other names: 7-Ethyl-6, 6b,  
 12 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido  
 13 (1', 2': 1, 2, azepino 4, 5-b) indole; tabernanthe iboga.  
 14 (21) Lysergic acid diethylamide (7315). Other name: LSD.  
 15 (22) Marijuana (7360).  
 16 (23) Mescaline (7381).  
 17 (24) Parahexyl (7374). Some trade or other names:  
 18 3-Hexyl-1-hydroxy-7, 8, 9, 10-Tetrahydro-6, 6,  
 19 9-trimethyl-6H-dibenzo (b,d) pyran; Snyhexyl.  
 20 (25) Peyote (7415), including:  
 21 (A) all parts of the plant that are classified botanically as  
 22 lophophora williamsii lemaire, whether growing or not;  
 23 (B) the seeds thereof;  
 24 (C) any extract from any part of the plant; and  
 25 (D) every compound, manufacture, salt, derivative, mixture, or  
 26 preparation of the plant, its seeds, or extracts.  
 27 (26) N-ethyl-3-piperidyl benzilate (7482). Other name: DMZ.  
 28 (27) N-hydroxy-3,4-methylenedioxyamphetamine (7402). Other  
 29 names: N-hydroxy-alpha-methyl-3,4  
 30 (methylenedioxy)phenethylamine; and N-hydroxy MDA.  
 31 (28) N-methyl-3-piperidyl benzilate (7484). Other name: LBJ.  
 32 (29) Psilocybin (7437).  
 33 (30) Psilocyn (7438).  
 34 (31) Tetrahydrocannabinols (7370), including synthetic  
 35 equivalents of the substances contained in the plant, or in the  
 36 resinous extractives of Cannabis, sp. and synthetic substances,  
 37 derivatives, and their isomers with similar chemical structure and  
 38 pharmacological activity such as:  
 39 (A)  $\pi^1$  cis or trans tetrahydrocannabinol, and their optical  
 40 isomers;  
 41 (B)  $\pi^6$  cis or trans tetrahydrocannabinol, and their optical  
 42 isomers; and



- 1 (C)  $\pi^3_4$  cis or trans tetrahydrocannabinol, and their optical  
 2 isomers.  
 3 Since nomenclature of these substances is not internationally  
 4 standardized, compounds of these structures, regardless of  
 5 numerical designation of atomic positions are covered. Other  
 6 name: THC.  
 7 (32) Ethylamine analog of phencyclidine (7455). Some trade or  
 8 other names: N-Ethyl-1-phenylcyclohexylamine;  
 9 (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl)  
 10 ethylamine; cyclohexamine; PCE.  
 11 (33) Pyrrolidine analog of phencyclidine (7458). Some trade or  
 12 other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCP<sub>y</sub>; PHP.  
 13 (34) Thiophene analog of phencyclidine (7470). Some trade or  
 14 other names: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl  
 15 Analog of Phencyclidine; TPCP.  
 16 ~~(35) Synthetic drugs (as defined in IC 35-31.5-2-321).~~  
 17 ~~(36)~~ **(35)** Salvia divinorum or salvinorin A, including:  
 18 (A) all parts of the plant that are classified botanically as salvia  
 19 divinorum, whether growing or not;  
 20 (B) the seeds of the plant;  
 21 (C) any extract from any part of the plant; and  
 22 (D) every compound, manufacture, salt, derivative, mixture, or  
 23 preparation of the plant, its seeds, or extracts.  
 24 ~~(37)~~ **(36)** 5-Methoxy-N,N-Dimethyltryptamine. Some trade or  
 25 other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole;  
 26 5-MeO-DMT.  
 27 ~~(38)~~ **(37)** 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).  
 28 ~~(39)~~ **(38)** 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).  
 29 ~~(40)~~ **(39)** 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C).  
 30 ~~(41)~~ **(40)** 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I).  
 31 ~~(42)~~ **(41)** 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine  
 32 (2C-T-2).  
 33 ~~(43)~~ **(42)** 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine  
 34 (2C-T-4).  
 35 ~~(44)~~ **(43)** 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H).  
 36 ~~(45)~~ **(44)** 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N).  
 37 ~~(46)~~ **(45)** 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine  
 38 (2C-P).  
 39 (e) Depressants. Unless specifically excepted in a rule adopted by  
 40 the board or unless listed in another schedule, any material, compound,  
 41 mixture, or preparation which contains any quantity of the following  
 42 substances having a depressant effect on the central nervous system,



1 including its salts, isomers, and salts of isomers whenever the existence  
 2 of such salts, isomers, and salts of isomers is possible within the  
 3 specific chemical designation:

4 Gamma-hydroxybutyric acid (other names include GHB;  
 5 gamma-hydroxybutyrate; 4-hydroxybutanoic acid; sodium  
 6 oxybate; sodium oxybutyrate) (2010)

7 Mecloqualone (2572)

8 Methaqualone (2565)

9 (f) Stimulants. Unless specifically excepted or unless listed in  
 10 another schedule, any material, compound, mixture, or preparation that  
 11 contains any quantity of the following substances having a stimulant  
 12 effect on the central nervous system, including its salts, isomers, and  
 13 salts of isomers:

14 ([+/-] cis-4-methylaminorex (([+/-]cis-4,5-  
 15 dihydro-4-methyl-5-phenyl-2-oxazolamine) (1590)

16 Aminorex (1585). Other names: aminoxaphen;  
 17 2-amino-5-phenyl-2-oxazoline; or  
 18 4,5-dihydro-5-phenyl-2-oxazolamine.

19 Cathinone (1235). Some trade or other names:  
 20 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone;  
 21 2-aminopropiophenone; and norephedrone.

22 Fenethylamine (1503).

23 N-Benzylpiperazine (7493). Other names: BZP; and  
 24 1-benzylpiperazine.

25 N-ethylamphetamine (1475).

26 Methcathinone (1237) Some other trade names:  
 27 2-Methylamino-1-Phenylpropan-1-one; Ephedrone;  
 28 Monomethylpropion; UR 1431.

29 N, N-dimethylamphetamine (1480). Other names: N,  
 30 N-alpha-trimethyl-benzeneethanamine; and N,  
 31 N-alpha-trimethylphenethylamine.

32 **(g) Synthetic drugs as defined in IC 35-31.5-2-321.**



## COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1272, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill be amended as follows:

Page 2, line 2, after "the" insert "**agency with consultation from the**".

Page 2, line 2, reset in roman "board".

Page 2, line 2, after "shall" insert "**may**".

Page 2, line 3, before "agency" reset in roman "randomly".

Page 2, line 3, delete "agency may randomly".

Page 2, line 3, reset in roman "more than one".

Page 2, line 4, reset in roman "percent (1%) but less than ten percent (10%)".

Page 2, line 4, delete "up to five percent (5%)".

and when so amended that said bill do pass.

(Reference is to HB 1272 as introduced.)

KIRCHHOFER

Committee Vote: yeas 12, nays 0.

---

 HOUSE MOTION

Mr. Speaker: I move that House Bill 1272 be amended to read as follows:

Page 3, between lines 19 and 20, begin a new paragraph and insert:  
 "SECTION 5. IC 25-27.5-5-2, AS AMENDED BY P.L.197-2011, SECTION 120, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2016]: Sec. 2. (a) A physician assistant must engage in a dependent practice with physician supervision. A physician assistant may perform, under the supervision of the supervising physician, the duties and responsibilities that are delegated by the supervising physician and that are within the supervising physician's scope of practice, including prescribing and dispensing drugs and medical devices. A patient may elect to be seen, examined, and treated by the supervising physician.

(b) If a physician assistant determines that a patient needs to be examined by a physician, the physician assistant shall immediately notify the supervising physician or physician designee.

**EH 1272—LS 6628/DI 109**



(c) If a physician assistant notifies the supervising physician that the physician should examine a patient, the supervising physician shall:

- (1) schedule an examination of the patient in a timely manner unless the patient declines; or
- (2) arrange for another physician to examine the patient.

(d) If a patient is subsequently examined by the supervising physician or another physician because of circumstances described in subsection (b) or (c), the visit must be considered as part of the same encounter except for in the instance of a medically appropriate referral.

(e) A supervising physician or physician assistant who does not comply with subsections (b) through (d) is subject to discipline under IC 25-1-9.

(f) A physician assistant's supervisory agreement with a supervising physician must:

- (1) be in writing;
- (2) include all the tasks delegated to the physician assistant by the supervising physician;
- (3) set forth the supervisory plans for the physician assistant, including the emergency procedures that the physician assistant must follow; and
- (4) specify the ~~name of the drug or drug classification being delegated to the physician assistant and the~~ protocol the physician assistant shall follow in prescribing a drug.

(g) The physician shall submit the supervisory agreement to the board. The physician assistant may prescribe a drug under the supervisory agreement unless the board denies the supervisory agreement. Any amendment to the supervisory agreement must be resubmitted to the board, and the physician assistant may operate under any new prescriptive authority under the amended supervisory agreement unless the agreement has been denied by the board.

(h) A physician or a physician assistant who violates the supervisory agreement described in this section may be disciplined under IC 25-1-9."

Renumber all SECTIONS consecutively.

(Reference is to HB 1272 as printed January 22, 2016.)

DAVISSON



## COMMITTEE REPORT

Madam President: The Senate Committee on Commerce & Technology, to which was referred House Bill No. 1272, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill DO PASS.

(Reference is to HB1272 as reprinted January 26, 2016.)

BUCK, Chairperson

Committee Vote: Yeas 8, Nays 0

---

 SENATE MOTION

Madam President: I move that Engrossed House Bill 1272 be amended to read as follows:

Page 1, line 8, delete "and agency".

Page 1, line 9, delete "(established by IC 25-1-5-3)".

Page 1, line 11, delete "board." and insert "board, **after which the board will forward the sworn statement to the agency (established by IC 25-1-5-3).**".

Page 1, line 15, delete "and" and insert "**or**".

Page 1, line 17, after "board's" insert "**or agency's**".

(Reference is to EHB 1272 as printed February 23, 2016.)

BROWN L

---

 SENATE MOTION

Madam President: I move that Engrossed House Bill 1272 be amended to read as follows:

Page 3, between lines 19 and 20, begin a new paragraph and insert:

"SECTION 5. IC 25-22.5-13.2-1, AS ADDED BY P.L.126-2013, SECTION 3, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2016]: Sec. 1. A facility that performs a mammography





examination shall, if the patient is determined by the facility to have an amount of breast and connective tissue in comparison to fat in the breast, ~~that would require follow up care or testing~~; notify the patient of the determination. The notice required under this section must be included with a summary of the written mammography report."

Renumber all SECTIONS consecutively.

(Reference is to EHB 1272 as printed February 23, 2016.)

MILLER PATRICIA

